Pathologic complete response (pCR) in HER2 positive breast cancer to sequential FEC 100-docetaxel (D) plus trastuzumab (T) neoadjuvant chemotherapy (NCT)
Year: 2009
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: P. J. Chollet, P. Dubray, X. Durando, C. Abrial, B. Nayl, M. Mouret-Reynier, C. Pomel, A. Bellière, S. Lemery, F. Penault-Llorca
Institution: Centre Jean Perrin
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W19634549